Opinion|Videos|December 27, 2023
Recent Updates in NCCN Guidelines for the Treatment of Recurrent or Metastatic Cervical Cancer
Leslie M. Randall, MD, reviews updates to the NCCN guidelines for cervical cancer, including the use of pembrolizumab in the second and third-line settings, the results of the KEYNOTE-826 trial, and the potential role of induction chemotherapy with weekly carboplatin and paclitaxel in the treatment of locally advanced cervical cancer.
Advertisement
Episodes in this series
Advertisement
Related to this article
CHMP has recommended EU approval of senaparib for advanced ovarian cancer based on FLAMES data.
Advertisement
Advertisement
Trending on OncLive
1
CLL Treatment Individualization Prompts Changes in Patient Evaluation and Care
2
Japan Approves Subcutaneous Pembrolizumab for All Approved Pembrolizumab Indications
3
FDA Grants Fast Track Designation to LYT-200 in R/R High-Risk MDS
4
Integrating Bispecific Antibodies Into Frontline Therapy for Newly Diagnosed Multiple Myeloma
5